Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Aptose Reports First Quarter 2026 Results
Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?
Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?
Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?
Aptose Announces Auditor Not Standing for Re-Appointment
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Aptose Reports Year End 2024 Results and Corporate Highlights
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
Aptose Announces Reverse Share Split
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Aptose Reports Results for the Third Quarter 2024
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript
Aptose Reports Results for the First Quarter 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
What Makes Aptose Biosciences (APTO) a New Buy Stock
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Why Is Aptose Biosciences (APTO) Stock Down Today?
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript
Aptose Reports Results for the Third Quarter 2023
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib